Spectrum of clonal hematopoiesis in VEXAS syndrome

•UBA1 mutations are primarily responsible for myeloid clonal expansion and both the inflammatory and hematologic phenotype in VEXAS.•Patients with VEXAS have an enrichment of typical CH mutations, particularly in DNMT3A and TET2. [Display omitted] Vacuoles, E1 enzyme, X-linked, autoinflammatory, som...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2023-07, Vol.142 (3), p.244-259
Hauptverfasser: Gutierrez-Rodrigues, Fernanda, Kusne, Yael, Fernandez, Jenna, Lasho, Terra, Shalhoub, Ruba, Ma, Xiaoyang, Alessi, Hugh, Finke, Christy, Koster, Matthew J., Mangaonkar, Abhishek, Warrington, Kenneth J., Begna, Kebede, Xie, Zhuoer, Ombrello, Amanda K., Viswanatha, David, Ferrada, Marcela, Wilson, Lorena, Go, Ronald, Kourelis, Taxiarchis, Reichard, Kaaren, Olteanu, Horatiu, Darden, Ivana, Hironaka, Dalton, Alemu, Lemlem, Kajigaya, Sachiko, Rosenzweig, Sofia, Calado, Rodrigo T., Groarke, Emma M., Kastner, Daniel L., Calvo, Katherine R., Wu, Colin O., Grayson, Peter C., Young, Neal S., Beck, David B., Patel, Bhavisha A., Patnaik, Mrinal M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 259
container_issue 3
container_start_page 244
container_title Blood
container_volume 142
creator Gutierrez-Rodrigues, Fernanda
Kusne, Yael
Fernandez, Jenna
Lasho, Terra
Shalhoub, Ruba
Ma, Xiaoyang
Alessi, Hugh
Finke, Christy
Koster, Matthew J.
Mangaonkar, Abhishek
Warrington, Kenneth J.
Begna, Kebede
Xie, Zhuoer
Ombrello, Amanda K.
Viswanatha, David
Ferrada, Marcela
Wilson, Lorena
Go, Ronald
Kourelis, Taxiarchis
Reichard, Kaaren
Olteanu, Horatiu
Darden, Ivana
Hironaka, Dalton
Alemu, Lemlem
Kajigaya, Sachiko
Rosenzweig, Sofia
Calado, Rodrigo T.
Groarke, Emma M.
Kastner, Daniel L.
Calvo, Katherine R.
Wu, Colin O.
Grayson, Peter C.
Young, Neal S.
Beck, David B.
Patel, Bhavisha A.
Patnaik, Mrinal M.
description •UBA1 mutations are primarily responsible for myeloid clonal expansion and both the inflammatory and hematologic phenotype in VEXAS.•Patients with VEXAS have an enrichment of typical CH mutations, particularly in DNMT3A and TET2. [Display omitted] Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic autoinflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 patients with VEXAS for CH in their peripheral blood (PB) and correlated the findings with clinical outcomes in 77 of them. UBA1mut were most common at hot spot p.M41 (median variant allele frequency [VAF] = 75%). Typical CH mutations cooccurred with UBA1mut in 60% of patients, mostly in DNMT3A and TET2, and were not associated with inflammatory or hematologic manifestations. In prospective single-cell proteogenomic sequencing (scDNA), UBA1mut was the dominant clone, present mostly in branched clonal trajectories. Based on integrated bulk and scDNA analyses, clonality in VEXAS followed 2 major patterns: with either typical CH preceding UBA1mut selection in a clone (pattern 1) or occurring as an UBA1mut subclone or in independent clones (pattern 2). VAF in the PB differed markedly between DNMT3A and TET2 clones (median VAF of 25% vs 1%). DNMT3A and TET2 clones associated with hierarchies representing patterns 1 and 2, respectively. Overall survival for all patients was 60% at 10 years. Transfusion-dependent anemia, moderate thrombocytopenia, and typical CH mutations, each correlated with poor outcome. In VEXAS, UBA1mut cells are the primary cause of systemic inflammation and marrow failure, being a new molecularly defined somatic entity associated with MDS. VEXAS-associated MDS is distinct from classical MDS in its presentation and clinical course. VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described disorder caused by mutations in UBA1 and is characterized by inflammation and hematologic disorders. In this month’s CME article, Gutierrez-Rodrigues and colleagues investigate the genomic landscape of myeloid-related mutations leading to clonal hematopoiesis (CH) in these patients. CH was detected in 60% of patients but
doi_str_mv 10.1182/blood.2022018774
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2805028201</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497123009862</els_id><sourcerecordid>2805028201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-3d59abd67df2a2d533e3d840e913dfefd054db63924dd26e5b5d264145ab934a3</originalsourceid><addsrcrecordid>eNp1kDtPwzAUhS0EoqWwM6GMLCnXrzzYqqo8pEoMBcRmOfGNMEriYCdI_fcEWmBiOst3jnQ-Qs4pzCnN2FVRO2fmDBgDmqWpOCBTKlkWAzA4JFMASGKRp3RCTkJ4A6CCM3lMJjyFTPCMTQnbdFj2fmgiV0Vl7VpdR6_Y6N51zmKwIbJt9Lx6WWyisG2Ndw2ekqNK1wHP9jkjTzerx-VdvH64vV8u1nHJc9bH3MhcFyZJTcU0M5Jz5CYTgDnlpsLKgBSmSEZWGMMSlIUcQ1AhdZFzofmMXO52O-_eBwy9amwosa51i24IimUggWXj9RGFHVp6F4LHSnXeNtpvFQX1ZUp9m1J_psbKxX59KBo0v4UfNSNwvQNw_Phh0atQWmxLNNaPypRx9v_1T2KEd2k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2805028201</pqid></control><display><type>article</type><title>Spectrum of clonal hematopoiesis in VEXAS syndrome</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Gutierrez-Rodrigues, Fernanda ; Kusne, Yael ; Fernandez, Jenna ; Lasho, Terra ; Shalhoub, Ruba ; Ma, Xiaoyang ; Alessi, Hugh ; Finke, Christy ; Koster, Matthew J. ; Mangaonkar, Abhishek ; Warrington, Kenneth J. ; Begna, Kebede ; Xie, Zhuoer ; Ombrello, Amanda K. ; Viswanatha, David ; Ferrada, Marcela ; Wilson, Lorena ; Go, Ronald ; Kourelis, Taxiarchis ; Reichard, Kaaren ; Olteanu, Horatiu ; Darden, Ivana ; Hironaka, Dalton ; Alemu, Lemlem ; Kajigaya, Sachiko ; Rosenzweig, Sofia ; Calado, Rodrigo T. ; Groarke, Emma M. ; Kastner, Daniel L. ; Calvo, Katherine R. ; Wu, Colin O. ; Grayson, Peter C. ; Young, Neal S. ; Beck, David B. ; Patel, Bhavisha A. ; Patnaik, Mrinal M.</creator><creatorcontrib>Gutierrez-Rodrigues, Fernanda ; Kusne, Yael ; Fernandez, Jenna ; Lasho, Terra ; Shalhoub, Ruba ; Ma, Xiaoyang ; Alessi, Hugh ; Finke, Christy ; Koster, Matthew J. ; Mangaonkar, Abhishek ; Warrington, Kenneth J. ; Begna, Kebede ; Xie, Zhuoer ; Ombrello, Amanda K. ; Viswanatha, David ; Ferrada, Marcela ; Wilson, Lorena ; Go, Ronald ; Kourelis, Taxiarchis ; Reichard, Kaaren ; Olteanu, Horatiu ; Darden, Ivana ; Hironaka, Dalton ; Alemu, Lemlem ; Kajigaya, Sachiko ; Rosenzweig, Sofia ; Calado, Rodrigo T. ; Groarke, Emma M. ; Kastner, Daniel L. ; Calvo, Katherine R. ; Wu, Colin O. ; Grayson, Peter C. ; Young, Neal S. ; Beck, David B. ; Patel, Bhavisha A. ; Patnaik, Mrinal M.</creatorcontrib><description>•UBA1 mutations are primarily responsible for myeloid clonal expansion and both the inflammatory and hematologic phenotype in VEXAS.•Patients with VEXAS have an enrichment of typical CH mutations, particularly in DNMT3A and TET2. [Display omitted] Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic autoinflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 patients with VEXAS for CH in their peripheral blood (PB) and correlated the findings with clinical outcomes in 77 of them. UBA1mut were most common at hot spot p.M41 (median variant allele frequency [VAF] = 75%). Typical CH mutations cooccurred with UBA1mut in 60% of patients, mostly in DNMT3A and TET2, and were not associated with inflammatory or hematologic manifestations. In prospective single-cell proteogenomic sequencing (scDNA), UBA1mut was the dominant clone, present mostly in branched clonal trajectories. Based on integrated bulk and scDNA analyses, clonality in VEXAS followed 2 major patterns: with either typical CH preceding UBA1mut selection in a clone (pattern 1) or occurring as an UBA1mut subclone or in independent clones (pattern 2). VAF in the PB differed markedly between DNMT3A and TET2 clones (median VAF of 25% vs 1%). DNMT3A and TET2 clones associated with hierarchies representing patterns 1 and 2, respectively. Overall survival for all patients was 60% at 10 years. Transfusion-dependent anemia, moderate thrombocytopenia, and typical CH mutations, each correlated with poor outcome. In VEXAS, UBA1mut cells are the primary cause of systemic inflammation and marrow failure, being a new molecularly defined somatic entity associated with MDS. VEXAS-associated MDS is distinct from classical MDS in its presentation and clinical course. VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described disorder caused by mutations in UBA1 and is characterized by inflammation and hematologic disorders. In this month’s CME article, Gutierrez-Rodrigues and colleagues investigate the genomic landscape of myeloid-related mutations leading to clonal hematopoiesis (CH) in these patients. CH was detected in 60% of patients but correlated poorly with progression to myeloid malignancy. CH did predict for poorer survival, perhaps through inflammatory sequelae.</description><identifier>ISSN: 0006-4971</identifier><identifier>ISSN: 1528-0020</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.2022018774</identifier><identifier>PMID: 37084382</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Clonal Hematopoiesis - genetics ; Dermatitis ; Humans ; Mutation ; Prospective Studies ; Retrospective Studies</subject><ispartof>Blood, 2023-07, Vol.142 (3), p.244-259</ispartof><rights>2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-3d59abd67df2a2d533e3d840e913dfefd054db63924dd26e5b5d264145ab934a3</citedby><orcidid>0000-0002-7966-6029 ; 0000-0001-5783-4485 ; 0000-0003-1266-9804 ; 0000-0003-1035-3662 ; 0000-0003-3116-4588 ; 0000-0003-2243-5315 ; 0000-0002-4648-5926 ; 0000-0001-8573-9434 ; 0000-0002-7325-8454 ; 0000-0003-2730-8593 ; 0000-0001-6998-662X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37084382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gutierrez-Rodrigues, Fernanda</creatorcontrib><creatorcontrib>Kusne, Yael</creatorcontrib><creatorcontrib>Fernandez, Jenna</creatorcontrib><creatorcontrib>Lasho, Terra</creatorcontrib><creatorcontrib>Shalhoub, Ruba</creatorcontrib><creatorcontrib>Ma, Xiaoyang</creatorcontrib><creatorcontrib>Alessi, Hugh</creatorcontrib><creatorcontrib>Finke, Christy</creatorcontrib><creatorcontrib>Koster, Matthew J.</creatorcontrib><creatorcontrib>Mangaonkar, Abhishek</creatorcontrib><creatorcontrib>Warrington, Kenneth J.</creatorcontrib><creatorcontrib>Begna, Kebede</creatorcontrib><creatorcontrib>Xie, Zhuoer</creatorcontrib><creatorcontrib>Ombrello, Amanda K.</creatorcontrib><creatorcontrib>Viswanatha, David</creatorcontrib><creatorcontrib>Ferrada, Marcela</creatorcontrib><creatorcontrib>Wilson, Lorena</creatorcontrib><creatorcontrib>Go, Ronald</creatorcontrib><creatorcontrib>Kourelis, Taxiarchis</creatorcontrib><creatorcontrib>Reichard, Kaaren</creatorcontrib><creatorcontrib>Olteanu, Horatiu</creatorcontrib><creatorcontrib>Darden, Ivana</creatorcontrib><creatorcontrib>Hironaka, Dalton</creatorcontrib><creatorcontrib>Alemu, Lemlem</creatorcontrib><creatorcontrib>Kajigaya, Sachiko</creatorcontrib><creatorcontrib>Rosenzweig, Sofia</creatorcontrib><creatorcontrib>Calado, Rodrigo T.</creatorcontrib><creatorcontrib>Groarke, Emma M.</creatorcontrib><creatorcontrib>Kastner, Daniel L.</creatorcontrib><creatorcontrib>Calvo, Katherine R.</creatorcontrib><creatorcontrib>Wu, Colin O.</creatorcontrib><creatorcontrib>Grayson, Peter C.</creatorcontrib><creatorcontrib>Young, Neal S.</creatorcontrib><creatorcontrib>Beck, David B.</creatorcontrib><creatorcontrib>Patel, Bhavisha A.</creatorcontrib><creatorcontrib>Patnaik, Mrinal M.</creatorcontrib><title>Spectrum of clonal hematopoiesis in VEXAS syndrome</title><title>Blood</title><addtitle>Blood</addtitle><description>•UBA1 mutations are primarily responsible for myeloid clonal expansion and both the inflammatory and hematologic phenotype in VEXAS.•Patients with VEXAS have an enrichment of typical CH mutations, particularly in DNMT3A and TET2. [Display omitted] Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic autoinflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 patients with VEXAS for CH in their peripheral blood (PB) and correlated the findings with clinical outcomes in 77 of them. UBA1mut were most common at hot spot p.M41 (median variant allele frequency [VAF] = 75%). Typical CH mutations cooccurred with UBA1mut in 60% of patients, mostly in DNMT3A and TET2, and were not associated with inflammatory or hematologic manifestations. In prospective single-cell proteogenomic sequencing (scDNA), UBA1mut was the dominant clone, present mostly in branched clonal trajectories. Based on integrated bulk and scDNA analyses, clonality in VEXAS followed 2 major patterns: with either typical CH preceding UBA1mut selection in a clone (pattern 1) or occurring as an UBA1mut subclone or in independent clones (pattern 2). VAF in the PB differed markedly between DNMT3A and TET2 clones (median VAF of 25% vs 1%). DNMT3A and TET2 clones associated with hierarchies representing patterns 1 and 2, respectively. Overall survival for all patients was 60% at 10 years. Transfusion-dependent anemia, moderate thrombocytopenia, and typical CH mutations, each correlated with poor outcome. In VEXAS, UBA1mut cells are the primary cause of systemic inflammation and marrow failure, being a new molecularly defined somatic entity associated with MDS. VEXAS-associated MDS is distinct from classical MDS in its presentation and clinical course. VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described disorder caused by mutations in UBA1 and is characterized by inflammation and hematologic disorders. In this month’s CME article, Gutierrez-Rodrigues and colleagues investigate the genomic landscape of myeloid-related mutations leading to clonal hematopoiesis (CH) in these patients. CH was detected in 60% of patients but correlated poorly with progression to myeloid malignancy. CH did predict for poorer survival, perhaps through inflammatory sequelae.</description><subject>Clonal Hematopoiesis - genetics</subject><subject>Dermatitis</subject><subject>Humans</subject><subject>Mutation</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><issn>0006-4971</issn><issn>1528-0020</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kDtPwzAUhS0EoqWwM6GMLCnXrzzYqqo8pEoMBcRmOfGNMEriYCdI_fcEWmBiOst3jnQ-Qs4pzCnN2FVRO2fmDBgDmqWpOCBTKlkWAzA4JFMASGKRp3RCTkJ4A6CCM3lMJjyFTPCMTQnbdFj2fmgiV0Vl7VpdR6_Y6N51zmKwIbJt9Lx6WWyisG2Ndw2ekqNK1wHP9jkjTzerx-VdvH64vV8u1nHJc9bH3MhcFyZJTcU0M5Jz5CYTgDnlpsLKgBSmSEZWGMMSlIUcQ1AhdZFzofmMXO52O-_eBwy9amwosa51i24IimUggWXj9RGFHVp6F4LHSnXeNtpvFQX1ZUp9m1J_psbKxX59KBo0v4UfNSNwvQNw_Phh0atQWmxLNNaPypRx9v_1T2KEd2k</recordid><startdate>20230720</startdate><enddate>20230720</enddate><creator>Gutierrez-Rodrigues, Fernanda</creator><creator>Kusne, Yael</creator><creator>Fernandez, Jenna</creator><creator>Lasho, Terra</creator><creator>Shalhoub, Ruba</creator><creator>Ma, Xiaoyang</creator><creator>Alessi, Hugh</creator><creator>Finke, Christy</creator><creator>Koster, Matthew J.</creator><creator>Mangaonkar, Abhishek</creator><creator>Warrington, Kenneth J.</creator><creator>Begna, Kebede</creator><creator>Xie, Zhuoer</creator><creator>Ombrello, Amanda K.</creator><creator>Viswanatha, David</creator><creator>Ferrada, Marcela</creator><creator>Wilson, Lorena</creator><creator>Go, Ronald</creator><creator>Kourelis, Taxiarchis</creator><creator>Reichard, Kaaren</creator><creator>Olteanu, Horatiu</creator><creator>Darden, Ivana</creator><creator>Hironaka, Dalton</creator><creator>Alemu, Lemlem</creator><creator>Kajigaya, Sachiko</creator><creator>Rosenzweig, Sofia</creator><creator>Calado, Rodrigo T.</creator><creator>Groarke, Emma M.</creator><creator>Kastner, Daniel L.</creator><creator>Calvo, Katherine R.</creator><creator>Wu, Colin O.</creator><creator>Grayson, Peter C.</creator><creator>Young, Neal S.</creator><creator>Beck, David B.</creator><creator>Patel, Bhavisha A.</creator><creator>Patnaik, Mrinal M.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7966-6029</orcidid><orcidid>https://orcid.org/0000-0001-5783-4485</orcidid><orcidid>https://orcid.org/0000-0003-1266-9804</orcidid><orcidid>https://orcid.org/0000-0003-1035-3662</orcidid><orcidid>https://orcid.org/0000-0003-3116-4588</orcidid><orcidid>https://orcid.org/0000-0003-2243-5315</orcidid><orcidid>https://orcid.org/0000-0002-4648-5926</orcidid><orcidid>https://orcid.org/0000-0001-8573-9434</orcidid><orcidid>https://orcid.org/0000-0002-7325-8454</orcidid><orcidid>https://orcid.org/0000-0003-2730-8593</orcidid><orcidid>https://orcid.org/0000-0001-6998-662X</orcidid></search><sort><creationdate>20230720</creationdate><title>Spectrum of clonal hematopoiesis in VEXAS syndrome</title><author>Gutierrez-Rodrigues, Fernanda ; Kusne, Yael ; Fernandez, Jenna ; Lasho, Terra ; Shalhoub, Ruba ; Ma, Xiaoyang ; Alessi, Hugh ; Finke, Christy ; Koster, Matthew J. ; Mangaonkar, Abhishek ; Warrington, Kenneth J. ; Begna, Kebede ; Xie, Zhuoer ; Ombrello, Amanda K. ; Viswanatha, David ; Ferrada, Marcela ; Wilson, Lorena ; Go, Ronald ; Kourelis, Taxiarchis ; Reichard, Kaaren ; Olteanu, Horatiu ; Darden, Ivana ; Hironaka, Dalton ; Alemu, Lemlem ; Kajigaya, Sachiko ; Rosenzweig, Sofia ; Calado, Rodrigo T. ; Groarke, Emma M. ; Kastner, Daniel L. ; Calvo, Katherine R. ; Wu, Colin O. ; Grayson, Peter C. ; Young, Neal S. ; Beck, David B. ; Patel, Bhavisha A. ; Patnaik, Mrinal M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-3d59abd67df2a2d533e3d840e913dfefd054db63924dd26e5b5d264145ab934a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Clonal Hematopoiesis - genetics</topic><topic>Dermatitis</topic><topic>Humans</topic><topic>Mutation</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gutierrez-Rodrigues, Fernanda</creatorcontrib><creatorcontrib>Kusne, Yael</creatorcontrib><creatorcontrib>Fernandez, Jenna</creatorcontrib><creatorcontrib>Lasho, Terra</creatorcontrib><creatorcontrib>Shalhoub, Ruba</creatorcontrib><creatorcontrib>Ma, Xiaoyang</creatorcontrib><creatorcontrib>Alessi, Hugh</creatorcontrib><creatorcontrib>Finke, Christy</creatorcontrib><creatorcontrib>Koster, Matthew J.</creatorcontrib><creatorcontrib>Mangaonkar, Abhishek</creatorcontrib><creatorcontrib>Warrington, Kenneth J.</creatorcontrib><creatorcontrib>Begna, Kebede</creatorcontrib><creatorcontrib>Xie, Zhuoer</creatorcontrib><creatorcontrib>Ombrello, Amanda K.</creatorcontrib><creatorcontrib>Viswanatha, David</creatorcontrib><creatorcontrib>Ferrada, Marcela</creatorcontrib><creatorcontrib>Wilson, Lorena</creatorcontrib><creatorcontrib>Go, Ronald</creatorcontrib><creatorcontrib>Kourelis, Taxiarchis</creatorcontrib><creatorcontrib>Reichard, Kaaren</creatorcontrib><creatorcontrib>Olteanu, Horatiu</creatorcontrib><creatorcontrib>Darden, Ivana</creatorcontrib><creatorcontrib>Hironaka, Dalton</creatorcontrib><creatorcontrib>Alemu, Lemlem</creatorcontrib><creatorcontrib>Kajigaya, Sachiko</creatorcontrib><creatorcontrib>Rosenzweig, Sofia</creatorcontrib><creatorcontrib>Calado, Rodrigo T.</creatorcontrib><creatorcontrib>Groarke, Emma M.</creatorcontrib><creatorcontrib>Kastner, Daniel L.</creatorcontrib><creatorcontrib>Calvo, Katherine R.</creatorcontrib><creatorcontrib>Wu, Colin O.</creatorcontrib><creatorcontrib>Grayson, Peter C.</creatorcontrib><creatorcontrib>Young, Neal S.</creatorcontrib><creatorcontrib>Beck, David B.</creatorcontrib><creatorcontrib>Patel, Bhavisha A.</creatorcontrib><creatorcontrib>Patnaik, Mrinal M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gutierrez-Rodrigues, Fernanda</au><au>Kusne, Yael</au><au>Fernandez, Jenna</au><au>Lasho, Terra</au><au>Shalhoub, Ruba</au><au>Ma, Xiaoyang</au><au>Alessi, Hugh</au><au>Finke, Christy</au><au>Koster, Matthew J.</au><au>Mangaonkar, Abhishek</au><au>Warrington, Kenneth J.</au><au>Begna, Kebede</au><au>Xie, Zhuoer</au><au>Ombrello, Amanda K.</au><au>Viswanatha, David</au><au>Ferrada, Marcela</au><au>Wilson, Lorena</au><au>Go, Ronald</au><au>Kourelis, Taxiarchis</au><au>Reichard, Kaaren</au><au>Olteanu, Horatiu</au><au>Darden, Ivana</au><au>Hironaka, Dalton</au><au>Alemu, Lemlem</au><au>Kajigaya, Sachiko</au><au>Rosenzweig, Sofia</au><au>Calado, Rodrigo T.</au><au>Groarke, Emma M.</au><au>Kastner, Daniel L.</au><au>Calvo, Katherine R.</au><au>Wu, Colin O.</au><au>Grayson, Peter C.</au><au>Young, Neal S.</au><au>Beck, David B.</au><au>Patel, Bhavisha A.</au><au>Patnaik, Mrinal M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spectrum of clonal hematopoiesis in VEXAS syndrome</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2023-07-20</date><risdate>2023</risdate><volume>142</volume><issue>3</issue><spage>244</spage><epage>259</epage><pages>244-259</pages><issn>0006-4971</issn><issn>1528-0020</issn><eissn>1528-0020</eissn><abstract>•UBA1 mutations are primarily responsible for myeloid clonal expansion and both the inflammatory and hematologic phenotype in VEXAS.•Patients with VEXAS have an enrichment of typical CH mutations, particularly in DNMT3A and TET2. [Display omitted] Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic autoinflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 patients with VEXAS for CH in their peripheral blood (PB) and correlated the findings with clinical outcomes in 77 of them. UBA1mut were most common at hot spot p.M41 (median variant allele frequency [VAF] = 75%). Typical CH mutations cooccurred with UBA1mut in 60% of patients, mostly in DNMT3A and TET2, and were not associated with inflammatory or hematologic manifestations. In prospective single-cell proteogenomic sequencing (scDNA), UBA1mut was the dominant clone, present mostly in branched clonal trajectories. Based on integrated bulk and scDNA analyses, clonality in VEXAS followed 2 major patterns: with either typical CH preceding UBA1mut selection in a clone (pattern 1) or occurring as an UBA1mut subclone or in independent clones (pattern 2). VAF in the PB differed markedly between DNMT3A and TET2 clones (median VAF of 25% vs 1%). DNMT3A and TET2 clones associated with hierarchies representing patterns 1 and 2, respectively. Overall survival for all patients was 60% at 10 years. Transfusion-dependent anemia, moderate thrombocytopenia, and typical CH mutations, each correlated with poor outcome. In VEXAS, UBA1mut cells are the primary cause of systemic inflammation and marrow failure, being a new molecularly defined somatic entity associated with MDS. VEXAS-associated MDS is distinct from classical MDS in its presentation and clinical course. VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described disorder caused by mutations in UBA1 and is characterized by inflammation and hematologic disorders. In this month’s CME article, Gutierrez-Rodrigues and colleagues investigate the genomic landscape of myeloid-related mutations leading to clonal hematopoiesis (CH) in these patients. CH was detected in 60% of patients but correlated poorly with progression to myeloid malignancy. CH did predict for poorer survival, perhaps through inflammatory sequelae.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37084382</pmid><doi>10.1182/blood.2022018774</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-7966-6029</orcidid><orcidid>https://orcid.org/0000-0001-5783-4485</orcidid><orcidid>https://orcid.org/0000-0003-1266-9804</orcidid><orcidid>https://orcid.org/0000-0003-1035-3662</orcidid><orcidid>https://orcid.org/0000-0003-3116-4588</orcidid><orcidid>https://orcid.org/0000-0003-2243-5315</orcidid><orcidid>https://orcid.org/0000-0002-4648-5926</orcidid><orcidid>https://orcid.org/0000-0001-8573-9434</orcidid><orcidid>https://orcid.org/0000-0002-7325-8454</orcidid><orcidid>https://orcid.org/0000-0003-2730-8593</orcidid><orcidid>https://orcid.org/0000-0001-6998-662X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2023-07, Vol.142 (3), p.244-259
issn 0006-4971
1528-0020
1528-0020
language eng
recordid cdi_proquest_miscellaneous_2805028201
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Clonal Hematopoiesis - genetics
Dermatitis
Humans
Mutation
Prospective Studies
Retrospective Studies
title Spectrum of clonal hematopoiesis in VEXAS syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T15%3A31%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spectrum%20of%20clonal%20hematopoiesis%20in%20VEXAS%20syndrome&rft.jtitle=Blood&rft.au=Gutierrez-Rodrigues,%20Fernanda&rft.date=2023-07-20&rft.volume=142&rft.issue=3&rft.spage=244&rft.epage=259&rft.pages=244-259&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.2022018774&rft_dat=%3Cproquest_cross%3E2805028201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2805028201&rft_id=info:pmid/37084382&rft_els_id=S0006497123009862&rfr_iscdi=true